REMARKS

Claims 1-4 and 6-10 are pending. No amendments have been made by way of the present submission; thus, no new matter has been added. Additionally, no new issues have been raised by way of the present submission, which would require additional search and/or consideration on the part of the Examiner.

In the event that the present submission does not place the application into condition for allowance, entry thereof is respectfully requested as placing the application into better form for appeal.

In view of the following remarks, Applicants respectfully request that the Examiner withdraw all rejections and allow the currently pending claims.

Objection to Claim 10

The Examiner has objected to claim 10 asserting that the recitation of the term "comprising" in a method claim is informal and should therefore be deleted. Applicants respectfully disagree with the Examiner. The term "comprising" in claim 10 is transitional language that is required in all claims, including method claims. Thus, there is nothing informal concerning the recitation of "comprising" in claim 10. The Examiner is therefore requested to withdraw this objection.

Serial No.: 10/060,203

Issues under 35 U.S.C. § 112, second paragraph

The Examiner has rejected claim 2 under 35 U.S.C. § 112, second paragraph for the reasons recited at pages 2-3 of the outstanding Office Action. Applicants respectfully traverse this rejection.

The Examiner points out that claim 1 requires a triarylamine containing 2 to 4 nitrogen atoms each forming a triarylamine. However, the Examiner asserts that in claim 2, formulas 1 and 4 do not contain 2 to 4 nitrogen atoms. Applicants respectfully disagree with the Examiner.

Formulas 1 and 4 as recited in claim 2 are as follows:

$$(Ar_1Ar_2 N-)_2-Ar_3$$
 (1)

$$(Ar_1Ar_2 N-)_4-Ar_5$$
 (4)

Formula 1 has 2 nitrogen atoms and formula 4 has 4 nitrogen atoms. Thus, the compounds of formula 1 and 4 fall within the requirement of "a triarylamine containing 2 to 4 nitrogen atoms each forming a triarylamine."

To clarify the nature of the compounds of formula 1 and 4, Applicants have re-written these formulas in a different configuration, shown below:

Serial No.: 10/060,203

$$Ar_2 \qquad Ar_3 - N \qquad Ar_1 \qquad (1)$$

$$Ar_1 \qquad Ar_1 \qquad Ar_2 \qquad Ar_3 \qquad Ar_4 \qquad Ar_5 \qquad Ar_5 \qquad Ar_5 \qquad Ar_6 \qquad Ar_6$$

$$Ar_{2}$$
 Ar_{1}
 Ar_{2}
 Ar_{5}
 Ar_{1}
 Ar_{2}
 Ar_{1}
 Ar_{2}
 Ar_{1}
 Ar_{2}
 Ar_{1}
 Ar_{2}
 Ar_{1}
 Ar_{2}
 Ar_{1}

In this configuration formula 1 clearly contains 2 nitrogen atoms each forming a triarylamine and formula 4 clearly contains 4 nitrogen atoms each forming a triarylamine. Accordingly, this rejection is improper and should be withdrawn.

In view of the above, Applicants respectfully submit that the present claims are in condition for allowance. Reconsideration and withdrawal of all outstanding rejections are respectfully requested. The issuance of a Notice of Allowability is also requested.

If the Examiner has any questions concerning this application, please contact Craig A. McRobbie, Registration No. 42,874 at the offices of Birch, Stewart, Kolasch & Birch, LLP.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional

Serial No.: 10/060,203

fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

(md & 6.81

GMM/CAM:mmi 1752-0154P

P. O. Box 747 Falls Church, VA 22040-0747 (703) 205-8000